BCL2 and diffuse large B-cell lymphoma: Additionally, in some instances, secondary genetic events in t(14;18) DLBCL may result in disruption of the BCL2 gene resulting in loss of BCL2 protein expression.304 However, high expression of BCL2 mRNA305 and BCL2 protein306 have been associated with poor outcomes in DLBCL; BCL2 “super-expressing” DLBCL may be associated with particularly poor outcomes.306 This has led to the empirical addition of venetoclax to various immuno-chemotherapy backbones in phase I/II clinical trials.